GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients

 GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access program, developed in partnership with leading biopharma companies, which aims to increase access to exome sequencing for pediatric epilepsy patients.

Through the patient access program, GeneDx is helping to ensure more equitable care across patient populations. While payor coverage for exome testing has improved, this program may help expand access of necessary genetic testing for pediatric epilepsy patients.

https://www.globenewswire.com/news-release/2024/06/05/2893732/0/en/GeneDx-Announces-Patient-Access-Program-to-Expand-Access-to-Exome-Testing-for-Pediatric-Epilepsy-Patients.html